Shares of Sunshine Heart Inc (NASDAQ:CHFS) have been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus price objective of $15.00 for the company, according to Zacks. Zacks has also assigned Sunshine Heart an industry rank of 170 out of 265 based on the ratings given to related companies.
Several brokerages have recently issued reports on CHFS. Zacks Investment Research lowered Sunshine Heart from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. ValuEngine raised Sunshine Heart from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 31st.
Sunshine Heart Company Profile
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.